IDIOPATHIC INFLAMMATORY MYOPATHY
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHY trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control TerminatedThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC